Abstract
Purpose
The purpose of this study was to determine whether the degree of prostate to rectal separation using a hydrogel spacer (HS) and its effect on decreasing rectal dose can be reproduced in the community setting.
Methods
Thirty one patients with cT1-3aN0M0 prostate adenocarcinoma receiving radical radiotherapy to 78 Gy were recruited to the study. The primary endpoint was the proportion of patients achieving at least 25% reduction in volume of rectum receiving 70 Gy (rV70). Other endpoints included degree of prostate to rectum separation, HS insertion-related adverse events and the proportion of patients with grade 1 or worse acute or late gastrointestinal (GI) and genitourinary (GU) toxicity.
Results
All patients had successful insertion of their HS with no peri-operative toxicity. The mean prostate–rectal separation achieved was 10.5 mm. Twenty nine (93.5%) patients achieved a reduction in rV70 of at least 25%. Acute grade 1 GI toxicity was reported in 3 patients. All symptoms had resolved by 3 months post RT. Late grade 1 GI toxicity was reported in one patient (3.2%) with bowel frequency occurring at 6 months and resolving by 12 months post RT. There was no grade 2 or 3 acute or late GI toxicity seen.
Conclusion
In conclusion, this study illustrates that the application and benefits of HS on reducing GI rectal dose endpoints and toxicities during prostate cancer RT can be reliably replicated in a community setting similar to centres participating in the randomised trial under high quality assurance trial monitoring.
Similar content being viewed by others
References
Dearnaley DP, Jovic G, Syndikus I, Khoo V, Cowan RA, Graham JD et al (2014) Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol 15(4):464–473
Spratt DE, Pei X, Yamada J, Kollmeier MA, Cox B, Zelefsky MJ (2013) Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 85(3):686–692
Beckendorf V, Guerif S, Le Prise E, Cosset JM, Bougnoux A, Chauvet B et al (2011) 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 80(4):1056–1063
Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR et al (2008) Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70(1):67–74
Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF et al (2006) Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24(13):1990–1996
Dearnaley DP, Khoo VS, Norman AR, Meyer L, Nahum A, Tait D et al (1999) Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 353(9149):267–272
Huang EH, Pollack A, Levy L, Starkschall G, Dong L, Rosen I et al (2002) Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 54(5):1314–1321
Michalski JM, Yan Y, Watkins-Bruner D, Bosch WR, Winter K, Galvin JM et al (2013) Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial. Int J Radiat Oncol Biol Phys 87(5):932–938
Ng M, Brown E, Williams A, Chao M, Lawrentschuk N, Chee R (2014) Fiducial markers and spacers in prostate radiotherapy: current applications. BJU Int 113(Suppl 2):13–20
Mariados N, Sylvester J, Shah D, Karsh L, Hudes R, Beyer D et al (2015) Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 92(5):971–977
Sidhom MA, Kneebone AB, Lehman M, Wiltshire KL, Millar JL, Mukherjee RK et al (2008) Post-prostatectomy radiation therapy: consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group. Radiother Oncol 88(1):10–19
Luo C, Yang CC, Narayan S, Stern RL, Perks J, Goldberg Z et al (2006) Use of benchmark dose-volume histograms for selection of the optimal technique between three-dimensional conformal radiation therapy and intensity-modulated radiation therapy in prostate cancer. Int J Radiat Oncol Biol Phys 66(4):1253–1262
van Gysen K, Kneebone A, Alfieri F, Guo L, Eade T (2014) Feasibility of and rectal dosimetry improvement with the use of SpaceOAR(R) hydrogel for dose-escalated prostate cancer radiotherapy. J Med Imaging Radiat Oncol 58(4):511–516
Prada PJ, Fernandez J, Martinez AA, de la Rua A, Gonzalez JM, Fernandez JM et al (2007) Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity modulated brachytherapy or EBRT for prostate cancer patients. Int J Radiat Oncol Biol Phys 69(1):95–102
Pinkawa M, Klotz J, Djukic V, Schubert C, Escobar-Corral N, Caffaro M et al (2013) Learning curve in the application of a hydrogel spacer to protect the rectal wall during radiotherapy of localized prostate cancer. Urology 82(4):963–968
Pinkawa M, Corral NE, Caffaro M, Piroth MD, Holy R, Djukic V et al (2011) Application of a spacer gel to optimize three-dimensional conformal and intensity modulated radiotherapy for prostate cancer. Radiother Oncol 100(3):436–441
Arcangeli S, Gambardella P, Agolli L, Monaco A, Dognini J, Regine G et al (2015) Stereotactic body radiation therapy salvage reirradiation of radiorecurrent prostatic carcinoma relapsed in the prostatic bed. Tumori 101(2):e57–e59
Vargas C, Martinez A, Kestin LL, Yan D, Grills I, Brabbins DS et al (2005) Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys 62(5):1297–1308
Marzi S, Arcangeli G, Saracino B, Petrongari MG, Bruzzaniti V, Iaccarino G et al (2007) Relationships between rectal wall dose-volume constraints and radiobiologic indices of toxicity for patients with prostate cancer. Int J Radiat Oncol Biol Phys 68(1):41–49
Hamstra DA, Mariados N, Sylvester J, Shah D, Karsh L, Hudes R et al (2017) Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial. Int J Radiat Oncol Biol Phys 97(5):976–985
Pinkawa M, Berneking V, Schlenter M, Krenkel B, Eble MJ (2017) Quality of life after radiation therapy for prostate cancer with a hydrogel spacer: 5-year results. Int J Radiat Oncol Biol Phys 99(2):374–377
Trifiletti DM, Garda AE, Showalter TN (2016) Implanted spacer approaches for pelvic radiation therapy. Expert Rev Med Devices 13(7):633–640
Author information
Authors and Affiliations
Contributions
MC: project development, data analysis, manuscript writing/editing. DLJ: project development, manuscript editing. VK: manuscript editing. NL: manuscript editing. HH: data management, data analysis. SS: data management. YC: data collection. AT: data collection. TP: data collection. SS: data collection. KM: data collection. ML: data collection. GK: data collection. CWC: data collection. FF: manuscript editing. DB: protocol development, manuscript editing.
Corresponding author
Ethics declarations
Research involving human participants
All procedures performed in this study involving human participants were in accordance with the ethical standards of the institution and with the 1964 Helsinki declaration or comparable ethical standards.
Conflict of interest
The authors declare that they have no conflict of interest.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Chao, M., Lim Joon, D., Khoo, V. et al. The use of hydrogel spacer in men undergoing high-dose prostate cancer radiotherapy: results of a prospective phase 2 clinical trial. World J Urol 37, 1111–1116 (2019). https://doi.org/10.1007/s00345-018-2502-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-018-2502-5